VEEA INC. (NASDAQ: VEEA) carries roughly 7.65 million post-split shares of pending supply stacked against a public float of just 1.85 million shares — an overhang equal to 414% of every freely tradeable share.
That ratio is the defining structural fact of this edge-computing company, which completed a 1-for-20 reverse stock split on August 28, 2026, to cure a Nasdaq minimum-bid-price deficiency. The board chose the maximum ratio shareholders had approved, signaling the severity of the prior dilution cycle. Crucially, authorized shares were not reduced proportionately, leaving approximately 27.5 million authorized against 3.11 million outstanding — a roughly 8.8-to-1 headroom that reloads the company's capacity to issue new stock.
Three Live Mechanisms
The actionable dilution risk is concentrated in three at-or-below-market facilities that can deliver shares into the float with little or no advance notice:
1. Roth ATM. An at-the-market facility — a program that lets the company sell newly issued shares directly into the open market through a broker — launched August 13 with $4.353 million of nominal capacity. At recent levels that capacity would represent roughly 2.55 million shares, or about 138% of the entire float. No per-sale disclosure is required.
2. White Lion convertible notes. Approximately $1.11 million in face value of unsecured notes held by White Lion Capital convert at 90% of the lowest volume-weighted average price over the prior ten trading days — meaning the conversion price drops automatically as the stock weakens, issuing progressively more shares. There is no disclosed floor price. At $1.71, this mechanic would produce roughly 722,000 shares — 39% of float. At half that level, the share count nearly doubles.
3. White Lion equity line of credit. A $25 million purchase agreement — a standby facility under which the company can compel the counterparty to buy newly issued shares — remains live through June 2027 with only $837,000 drawn through March. Its most aggressive pricing tier is the lowest traded price on the purchase date. A 19.99% exchange cap limits aggregate issuance to roughly 622,000 shares unless shareholders approve an increase at a vote deadlined for September 30.
White Lion occupies both sides of this structure simultaneously: it is the convertible-note holder and the equity-line counterparty, giving it two independent below-market entry points into the same float.
What Is Inert — and Why It Still Matters
The company's entire 3.83-million-share warrant book is deep out of the money, with the lowest strike at $6.20 and a weighted-average exercise price near $83.20. Both preferred series — representing 2.77 million as-converted shares, or 150% of float — convert at $10.06 and $6.20 respectively. Voluntary exercise or conversion at these levels would destroy value for the holders.
That inertness is the reason the dilution risk grade sits at 7 out of 10 — Elevated — rather than higher. But the overhang is not irrelevant. A $75 million shelf registration — a pre-filed SEC authorization to issue securities — is currently constrained by a "baby-shelf" cap that limits sales to roughly one-third of non-affiliate market value per year. That constraint vanishes entirely if non-affiliate market value ever exceeds $75 million, converting the shelf from a gated facility into an uncapped issuance vehicle.
Insider Concentration
Affiliates — principally NLabs Inc. and entities tied to CEO Allen Salmasi — hold 40.6% of shares outstanding on an issued basis and approximately 71% of voting power on a fully converted basis. NLabs has settled every prior loan to the company in equity or preferred stock rather than cash. It issued $1.75 million of fresh demand notes in July and August 2026, all maturing December 31 — the likeliest trigger for yet another equity-settlement transaction.